HLB Therapeutics Co.,Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was KRW 0.00006 million compared to KRW 0.0009 million a year ago. Net income was KRW 159.56 million compared to net loss of KRW 1,216.69 million a year ago.

Basic earnings per share from continuing operations was KRW 8.58 compared to basic loss per share from continuing operations of KRW 17.86 a year ago. Diluted earnings per share from continuing operations was KRW 8.55. Basic earnings per share was KRW 8.58 compared to basic loss per share of KRW 17.86 a year ago.

Diluted earnings per share was KRW 8.55.